Cohort studycited by the Tayebat archiveabstract only checked A-ODD-15 standard review
Stomach and bowel side effects of weight-loss injections
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Overview
Sodhi M et al.. JAMA 2023 · PMID 37796527 · DOI 10.1001/jama.2023.19574
Not verified (no abstract).
Does the study support the specific claim? Unclear · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
GI adverse events with GLP-1 RAs used for weight loss (per title)
- How was the study done?
Research letter; retrospective cohort (no abstract in PubMed; full text could not be retrieved)
- How many people, animals or samples were studied?
not verifiable; not verifiable
- What was actually found?
Not verified.
- How large was the observed effect?
not verified
- What do the results mean in everyday life?
GI side effects are common with GLP-1 RAs (RCTs).
- What are the study's limitations?
Not read
- What does it say about Elawady's specific claim?
Background for C-ODD-04.
- Do the results apply to Germany and Europe?
unknown
- What can explicitly not be concluded from this study?
Anything quantitative.
Scientific in-depth review
1. Full reference
- Authors
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M
- Journal
- JAMA
- Year
- 2023
- Identifier
- PMID 37796527 DOI 10.1001/jama.2023.19574 · PMC10557026
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
GI adverse events with GLP-1 RAs used for weight loss (per title)
3. Study design and population
- Study design
- Cohort study – Research letter; retrospective cohort (no abstract in PubMed; full text could not be retrieved)
- Population
not verifiable
- Country
not verifiable
- Period
not verifiable
- Sample size
not verifiable
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
GLP-1 receptor agonists for weight loss
- Comparator
not verifiable
- Endpoints
Gastrointestinal adverse events (per title)
- Statistical methods
not verifiable
5. Actual results
- Results
No abstract; numbers not verified.
- Absolute risks
not reported
- Authors' conclusion
Not verifiable from the record.
6. Strengths
- Published in JAMA
7. Weaknesses
- Not read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Not read.
9. Assessment of the statistical interpretation
not assessable
10. Relevance to the specific claim
Background for C-ODD-04.
11. Independent contrary findings
12. Transferability to Germany and Europe
unknown
13. Overall methodological judgement
Not assessed.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | unknown |
| Regional transferability | unknown |
| Adequacy of the interpretation (by the archive) | not verifiable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies with mixed or unclear results
- Every major class of glucose-lowering drug (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists) carries a documented signal of serious harm in the peer-reviewed literature. – Studies supporting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography for 'oral-diabetes-drugs' without its own interpretation; used as support for the claim that every drug class carries documented harm. The archive summary mentions gastroparesis.
- A. What was actually studied?
GI adverse events with GLP-1 RAs used for weight loss (per title)
- B. What did the authors find?
Not verified.
- C. What conclusions do the authors themselves draw?
Not verifiable from the record.
- D. What does the archive derive from it?
Support for 'gastroparesis' harm of GLP-1 RAs.
- E. Is this derivation scientifically justified?
Not verifiable in this audit; GI adverse effects of GLP-1 RAs are well known from RCTs (I-ODD-07).
- Adequacy of the interpretation (by the archive)
- not verifiable